Loading…
Loading…
EQUITY / NASDAQ · XNCM
Immix Biopharma, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗9.68 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 9.68 USD · Volume 2,548,216
21 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -12,456,343 USD | -6,717,705 USD | — |
| Net income | -11,557,002 USD | -6,622,563 USD | — |
| Cash and cash equivalents | 225,491,985 USD | — | — |
| Total liabilities | 10,192,343 USD | — | — |
| Total equity | 228,916,553 USD | 4,653,031 USD | +4,819.73% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 101/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD | 2025 / Quarter 201/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 225,491,985 USD | — | — | 93,928,566 USD | 15,947,308 USD | — | — | — |
| Net incomeIncome statement | -11,557,002 USD | -21,643,689 USD | -10,086,687 USD | -29,400,000 USD | -7,585,692 USD | -18,750,783 USD | -6,622,563 USD | -11,165,091 USD |
| Operating profitIncome statement | -12,456,343 USD | -23,260,198 USD | — | — | -7,662,509 USD | -19,063,139 USD | -6,717,705 USD | -11,400,630 USD |
| Total assetsBalance sheet | 239,108,896 USD | — | — | 104,840,341 USD | 20,080,604 USD | — | — | — |
| Total equityBalance sheet | 228,916,553 USD | — | 84,364,056 USD | 93,796,170 USD | 8,264,970 USD | — | 4,653,031 USD | — |
| Total liabilitiesBalance sheet | 10,192,343 USD | — | — | 11,044,171 USD | 11,815,634 USD | — | — | — |
| Capital expendituresCash flow statement | — | 53,529 USD | — | — | — | 567,799 USD | — | 195,343 USD |
| Financing cash flowCash flow statement | — | 155,245,437 USD | — | — | — | 11,718,263 USD | — | 1,110,116 USD |
| Investing cash flowCash flow statement | — | -2,131,172 USD | — | — | — | -567,799 USD | — | -195,343 USD |
| Operating cash flowCash flow statement | — | -21,562,698 USD | — | — | — | -12,900,697 USD | — | -6,994,921 USD |
| Report source | Open report ↗ Published: 08/07/2026 | Open report ↗ Published: 08/07/2026 | Open report ↗ Published: 08/07/2026 | Open report ↗ Published: 05/07/2026 | Open report ↗ Published: 11/07/2025 | Open report ↗ Published: 11/07/2025 | Open report ↗ Published: 08/07/2026 | Open report ↗ Published: 08/07/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.